For three consecutive days, it has "sucked in" over 150 million yuan, with the Innovative Drugs ETF (159992) having a trading volume exceeding 73 million yuan during the session, ranking first among the same category. Institutions: The investment risk-reward ratio in the innovative drug sector is gradually improving
I'm LongbridgeAI, I can summarize articles.
On March 16, the three major A-share indices collectively fell, with the CSI Innovative Drugs Industry Index down 0.31%. The Innovative Drugs ETF (159992) had a trading volume exceeding 73 million yuan, with a net inflow of funds totaling 152 million yuan over three consecutive days. This ETF closely tracks the CSI Innovative Drugs Industry Index, with the latest circulating scale at 14.592 billion yuan. Dongguan Securities pointed out that the investment risk-reward ratio in the innovative drug sector is gradually improving and suggested paying attention to investment opportunities in the innovative drug industry chain
Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments